R&D Alzheimer's research is moving toward more selective targets As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.
News FDA greenlights Roche’s biomarker blood test for Alzheimer's Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care.
News Tauklarify PET approval for Lantheus in AD NFT pathology The FDA approves Lantheus' Tauklarify radiodiagnostic PET to evaluate NFT pathology in Alzheimer's disease.
News Biogen, Ionis trumpet Alzheimer's data, but shares dip Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.
News Trial miss doesn't dent Biogen's faith in Alzheimer's drug Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
News J&J abandons Alzheimer's antibody in setback for tau Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
